Clinical Trials Insight: 700016990

Trial Profile

Clinical Trials Insight: 700016990

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Feb 2008

At a glance

  • Drugs Monoclonal antibody 1D09C3 (Primary)
  • Indications Lymphoproliferative disorders
  • Focus Adverse reactions
  • Sponsors Agennix AG
  • Most Recent Events

    • 25 Feb 2008 GPC Biotech has discontinued internal development of 1D09C3.
    • 27 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top